Lamivudine/raltegravir
| Combination of | |
|---|---|
| Lamivudine | Reverse-transcriptase inhibitor |
| Raltegravir | Integrase inhibitor |
| Clinical data | |
| Trade names | Dutrebis |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| KEGG | |
Lamivudine/raltegravir, sold under the brand name Dutrebis, is a fixed-dose combination antiretroviral medication used in the treatment of HIV/AIDS.[1] It contains lamivudine and raltegravir. It is taken by mouth.[1] Side effects may include lactic acidosis, pancreatitis, liver failure, and severe skin rashes.[1] It was approved for medical use in the United States in 2015.[1][2]
Lamivudine/raltegravir is not available in the United States.[3]
References
[edit]- ^ a b c d "Dutrebis (lamivudine and raltegravir)" (PDF). U.S. Food and Drug Administration (FDA). Retrieved 10 December 2017.
- ^ "Dutrebis (lamivudine and raltegravir) tablet". U.S. Food and Drug Administration (FDA). 11 April 2016. Retrieved 24 January 2020.
- ^ "Dutrebis (lamivudine and raltegravir) FDA Approval History". Drugs.com. 6 February 2015. Retrieved 24 January 2020.
External links
[edit]- "Lamivudine mixture with raltegravir". Drug Information Portal. U.S. National Library of Medicine.
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |